Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
cancer
clinical trials
detroit blog main
detroit top stories
fda
3
×
indiana blog main
indiana top stories
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
3
×
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biotech
larotrectinib
loxo oncology
roche
american society of clinical oncology (asco)
anti-inflammatory drugs
arcturus therapeutics
arena pharmaceuticals
avrobio
blueprint medicines
brexanolone
What
cancer
3
×
drug
3
×
fda
medicine
ahead
ambien
american
annual
approved
asco
attendees
attention
biotech
camp’s
cash
chicago
city
clinical
combinations
community’s
days
deeper
dna
eisai
expanding
fingerprint
flags
focus
genetic
going
higher
home
incidence
key
kicks
lorcaserin
loss
market
marketing
matter
Language
unset
Current search:
fda
×
drug
×
" seattle blog main "
×
cancer
×
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
5 years ago
Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More